WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference, fireside chat on Tuesday, November 11, 2025, at 8:00 a.m. ET in Boston.Stifel 2025 Healthcare Conference, fireside chat on We ...

Core Insights - Syndax Pharmaceuticals announced the acceptance of 23 abstracts, including six oral presentations, for the 67th American Society of Hematology (ASH) Annual Meeting, highlighting the company's advancements in menin inhibition and CSF-1R inhibition [1][2] Revumenib - Revumenib abstracts demonstrate promising results across various acute leukemia subtypes, including relapsed/refractory (R/R) settings and post-HSCT scenarios [1][2] - New frontline datasets will showcase the tolerability of Revumenib in combination with standard therapies, achieving high rates of complete remission and minimal residual disease (MRD) negativity [2][5] - The first real-world evidence for a menin inhibitor will be presented, along with a retrospective review of its use in post-transplant settings [2][5] - Key presentations include a Phase 2 study of Revumenib combined with venetoclax and decitabine/cedazuridine in newly diagnosed acute myeloid leukemia (AML) [7] - Additional presentations will cover efficacy and safety by leukemia type in patients with R/R KMT2Ar acute leukemia [7] Axatilimab - Axatilimab abstracts will focus on its long-term benefits in R/R chronic graft-versus-host disease (GVHD) and its tolerability when combined with ruxolitinib in newly diagnosed chronic GVHD [1][2] - An oral presentation will detail the safety and feasibility of transitioning dosing from 0.3 mg/kg every 2 weeks to 0.6 mg/kg every 4 weeks in the pivotal Phase 2 AGAVE-201 trial [4][10] - Presentations will also include interim safety analyses from a Phase 2 trial of axatilimab combined with ruxolitinib in newly diagnosed chronic GVHD [8][10] Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, with a pipeline that includes Revuforj (revumenib) and Niktimvo (axatilimab) [44] - The company is committed to advancing its clinical trials across various treatment landscapes, aiming to unlock the full potential of its product candidates [44]

Core Insights - Syndax Pharmaceuticals will report its third quarter 2025 financial results and provide a business update on November 3, 2025 [1] - A conference call and live audio webcast will be hosted by Syndax's management at 4:30 p.m. ET on the same day [1] Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [3] - The company's pipeline includes Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the CSF-1 receptor [3] - Syndax is committed to advancing cancer care and is conducting several clinical trials across various treatment stages [3]

Core Insights - Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on developing innovative cancer therapies and will present at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025 [1][2] Company Overview - Adlai Nortye operates globally with R&D centers in the U.S. and China, advancing a portfolio of innovative drug candidates in two key therapeutic areas: next-generation PD-1/L1 modulation and RAS-targeted therapies [3] - Key drug candidates include AN8025, a multifunctional fusion protein for T cell and antigen-presenting cell modulation; AN4005, a first-in-class oral small-molecule PD-L1 inhibitor; AN9025, an oral pan-RAS(ON) inhibitor; and AN4035, a novel CEACAM5-targeting antibody-drug conjugate [3]

Core Insights - Starpharma has signed a collaboration and license agreement with Genentech to develop cancer therapies using its proprietary DEP drug delivery technology [1] - The agreement includes an upfront payment of USD $5.5 million and potential milestones totaling up to USD $564 million, along with tiered royalties on global net sales [2][3] Company Overview - Starpharma is an innovative Australian biotechnology company focused on developing dendrimer-drug conjugates that incorporate Genentech medicines for oncology targets [3] - The DEP platform technology offers benefits such as improved solubility, increased efficacy, pharmacokinetic control, and better toxicity profiles, applicable to various drug classes [4] Strategic Goals - A key strategic priority for Starpharma is to establish high-impact partnerships to maximize the potential of its DEP platform, aiming to expand market reach and improve patient therapies [7] - The collaboration with Genentech is seen as a recognition of Starpharma's technology and a continuation of three years of collaborative research focused on cancer therapies [5][6]

Core Insights - Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that target specific vulnerabilities in cancer cells while minimizing damage to healthy cells [1][2] Presentation Details - Aprea will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 3:30 PM ET, located at the Lotte New York Palace Hotel [2] - A webcast of the presentation will be available for 90 days on the Aprea Investors page [2] Company Overview - Aprea's mission is to create novel cancer therapies that directly target cancer cells, reducing toxicity risks associated with conventional treatments [2] - The company's lead programs include APR-1051, an oral small-molecule inhibitor of WEE1 kinase, and ATRN-119, a macrocyclic small molecule ATR inhibitor, both in clinical development for solid tumor indications [2]

Company Overview - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a clinical-stage biopharmaceutical company focused on developing cancer therapies, particularly for hematologic malignancies [1] - The company's pipeline includes two candidates: Galinpepimut-S (GPS) and SLS009 (tambiciclib) [1] Product Pipeline - Galinpepimut-S (GPS) is an immunotherapy currently in Phase 3 clinical trials for acute myeloid leukemia (AML) [1] - SLS009 (tambiciclib) is another candidate in the company's pipeline, although specific details about its development stage are not provided [1]

Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on advancing innovative cancer therapies [3] - The company's pipeline includes FDA-approved therapies such as Revuforj (revumenib), a menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor [3] Upcoming Financial Results - Syndax Pharmaceuticals will report its second quarter 2025 financial results and provide a business update on August 4, 2025 [1] - A conference call and live audio webcast will be hosted by the management at 4:30 p.m. ET on the same day [1] Accessing the Conference Call - The live audio webcast and accompanying slides can be accessed through the Events & Presentations page on the company's website [2] - Domestic and international dial-in numbers are provided for the conference call, with a specific Conference ID: Syndax2Q25 [2] - A replay of the conference call will be available approximately 24 hours after the event and will remain accessible for 90 days [2]

Group 1 - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [2] - The company's pipeline includes FDA-approved therapies such as Revuforj (revumenib), a menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor [2] - Syndax is committed to advancing cancer care and is conducting several clinical trials across various treatment stages [2] Group 2 - Michael A. Metzger, CEO of Syndax, and the management team will participate in investor conferences, including the Jefferies Global Healthcare Conference on June 5, 2025, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025 [1][3] - A live webcast of the fireside chats will be available on the company's website, with replays accessible for a limited time [1]

Company Overview - BeyondSpring Inc. is a clinical-stage global biopharmaceutical company focused on developing cancer therapies, particularly its lead asset Plinabulin, which is in late-stage clinical development for non-small cell lung cancer (NSCLC) and other cancer indications [3] Study Announcement - BeyondSpring announced a poster presentation on the 303 Study, an investigator-initiated study supported by Merck, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 30 to June 3 in Chicago, IL [1] 303 Study Details - The 303 Study is an open-label, single-arm Phase 2 study evaluating the efficacy and safety of Plinabulin in combination with docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC who have progressed after anti-PD-(L)1 inhibitor therapy [4] - The study involves 47 enrolled patients and is conducted at Peking Union Medical College Hospital in Beijing, China, with Dr. Mengzhao Wang as the principal investigator [4] - The primary endpoint is the investigator-based overall response rate (ORR), while secondary endpoints include progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safety [4] Presentation Details - The presentation will take place on May 31, 2025, from 1:30 PM to 4:30 PM CDT at McCormick Place Convention Center, focusing on initial efficacy and safety results related to immune re-sensitization [5]